<SEC-DOCUMENT>0001564590-20-032445.txt : 20200716
<SEC-HEADER>0001564590-20-032445.hdr.sgml : 20200716
<ACCEPTANCE-DATETIME>20200716084015
ACCESSION NUMBER:		0001564590-20-032445
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200716
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200716
DATE AS OF CHANGE:		20200716

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		201030812

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582514400

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hrtx-8k_20200716.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-07-16T05:17:58.7578354+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : 6bb28e030a8f480c8f036c0d59d66bf2 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:hrtx="http://www.herontx.com/20200716" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
hrtx-8k_20200716.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000818033_20200716_20200716">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000818033_20200716_20200716">0000818033</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="hrtx-20200716.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000818033_20200716_20200716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-16</xbrli:startDate>
					<xbrli:endDate>2020-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt #000000;padding-bottom:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000818033_20200716_20200716">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000818033_20200716_20200716" format="ixt:datemonthdayyearen">July 16, 2020</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000818033_20200716_20200716">Heron Therapeutics, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000818033_20200716_20200716" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000818033_20200716_20200716">001-33221</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:29.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000818033_20200716_20200716">94-2875566</ix:nonNumeric></p></td>
</tr>
<tr style="height:21.15pt;">
<td valign="top" style="width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:29.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:56.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000818033_20200716_20200716">4242 Campus Point Court</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0000818033_20200716_20200716">Suite 200</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0000818033_20200716_20200716">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressStateOrProvince" contextRef="C_0000818033_20200716_20200716">CA</ix:nonNumeric></p></td>
<td valign="bottom" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityAddressPostalZipCode" contextRef="C_0000818033_20200716_20200716">92121</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:56.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code <ix:nonNumeric id="F_000014" name="dei:CityAreaCode" contextRef="C_0000818033_20200716_20200716">(858)</ix:nonNumeric> <ix:nonNumeric id="F_000015" name="dei:LocalPhoneNumber" contextRef="C_0000818033_20200716_20200716">251-4400</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:WrittenCommunications" contextRef="C_0000818033_20200716_20200716" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SolicitingMaterial" contextRef="C_0000818033_20200716_20200716" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementTenderOffer" contextRef="C_0000818033_20200716_20200716" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000818033_20200716_20200716" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39.92%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:22.6%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:34.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:39.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0000818033_20200716_20200716">Common Stock, par value $0.01 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0000818033_20200716_20200716">HRTX</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:34.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0000818033_20200716_20200716" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000818033_20200716_20200716" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt #000000;padding-bottom:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01 Other Events.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 16, 2020, Heron Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing <span style="color:#1E1E1E;">the initiation of the </span><span style="color:#000000;">GUARDS-1 </span><span style="color:#1E1E1E;">Study, a Phase 2 clinical study evaluating CINVANTI<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (&#8220;COVID-19&#8221; and the &#8220;Press Release&#8221;, respectively). </span><span style="color:#000000;">The study initiation follows </span><span style="color:#1E1E1E;">clearance from the U.S. Food and Drug Administration of the Company&#8217;s Investigational New Drug application for CINVANTI for the treatment of COVID-19. </span><span style="Background-color:#FFFFFF;">A copy of the Press Release is filed herewith as Exhibit 99.1</span>.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01 Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:89%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrtx-ex991_6.htm"><span style="text-decoration:underline;">Press Release, dated July 16, 2020</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <span style="color:#000000;">July 16, 2020</span></p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Szekeres</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Szekeres</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal, Business, and Administrative Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hrtx-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrtx-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2odmt0mwibo000001.jpg" title="" alt="" style="width:181px;height:71px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk480203125"></a><font style="Background-color:#FFFFFF;">Heron Therapeutics Announces Initiation of</font></p>
<p style="text-align:center;margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;"> Phase 2 Clinical Study of CINVANTI<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup>for the Treatment of COVID-19</font></p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAN DIEGO, July 16, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, <font style="color:#1E1E1E;">today announced the initiation of the </font>GUARDS-1 <font style="color:#1E1E1E;">Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). </font>The study initiation follows clearance from the U.S. Food and Drug Administration (FDA) of Heron&#8217;s Investigational New Drug application for CINVANTI for the treatment of COVID-19.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI is an intravenous formulation of aprepitant, a substance P/neurokinin-1 (<font style="color:#1E1E1E;">NK<sub style="font-size:85%; vertical-align:bottom">1</sub></font>) receptor antagonist (RA) approved for use for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Substance P, and its receptor <font style="color:#1E1E1E;">NK<sub style="font-size:85%; vertical-align:bottom">1</sub></font>, is distributed throughout the body in the cells of many tissues and organs, including the lungs. COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with lower respiratory tract inflammation that often progresses to Acute Respiratory Distress Syndrome (ARDS). ARDS is associated with high mortality.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron&#8217;s rationale for the investigation of CINVANTI for the treatment of COVID-19 is based on multiple potential mechanisms for activity. Suppressing the cytokine storm could be a crucial step to prevent the clinical deterioration of patients with COVID-19. Administration of aprepitant injectable emulsion to these patients is expected to decrease the production and release of inflammatory cytokines mediated by the binding of substance P to <font style="color:#1E1E1E;">NK<sub style="font-size:85%; vertical-align:bottom">1</sub></font> receptors, which could prevent the progression of lung injury to ARDS. A hallmark of COVID-19 is a non-productive neurogenic cough, likely due to the increased susceptibility of lung tissue to neurogenic inflammation caused by the disease. Recent studies have demonstrated that administration of oral aprepitant resulted in significantly decreased severity of cough in patients with neurogenic cough associated with advanced lung cancer. Additionally, aprepitant may have direct antiviral activity. Using a computational screening approach, aprepitant was found to have the ability to form hydrogen bonds to key residues within the binding pocket of the main protease of SARS-CoV-2, which is a key enzyme required for replication. CINVANTI is approved for administration as a 2-minute intravenous injection. For these potential benefits, the plasma concentrations of aprepitant produced with the 2-minute intravenous injection of CINVANTI could provide a unique advantage over other methods of administration. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GUARDS-1, also referred to as Study HTX-019-202, is a randomized, placebo-controlled, double-blinded, Phase 2 study designed to investigate the efficacy and safety of adding daily dosing of CINVANTI for 14 days as a <font style="color:#1E1E1E;">2-minute intravenous injection</font> to standard of care to reduce mortality and the need for assisted ventilation in early hospitalized adult patients with a confirmed SARS&#8209;CoV-2 infection. The use of remdesivir through the Emergency Use Authorization and dexamethasone as standard of care are both permitted in the study. The study will include up to approximately 100 adult patients who are hospitalized with a confirmed SARS-CoV-2 infection less than 24 hours prior to randomization. Importantly, the participating</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2odmt0mwibo000001.jpg" title="" alt="" style="width:181px;height:71px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical study sites have a high concen</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tration of racial and ethnic minority patients affected by COVID-19.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The COVID-19 pandemic has impacted millions of Americans. With the rate of hospitalization increasing in many states, many intensive care units (ICUs) are reaching capacity. Identifying marketed drugs that may keep more patients out of the ICUs is the most efficient way to impact the current crisis,&#8221; said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron. &#8220;With an existing commercial supply chain for CINVANTI and a positive safety profile in over 1 million single-dose administrations to patients with cancer who also receive dexamethasone, we are hopeful that we can deliver an effective therapeutic option for patients with COVID-19.&#8221;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About CINVANTI (Aprepitant) Injectable Emulsion</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, a substance P/neurokinin-1 (NK<sub style="font-size:85%; vertical-align:bottom">1</sub>) receptor antagonist (RA). CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK<sub style="font-size:85%; vertical-align:bottom">1</sub>&#160;RA to significantly reduce nausea and vomiting in both the acute phase (0&#8211;24 hours after chemotherapy) and the delayed phase (24&#8211;120 hours after chemotherapy). The&#160;FDA-approved dosing administration included in&#160;the United States&#160;prescribing information for CINVANTI is a 30-minute IV infusion or a 2-minute IV injection.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI is under investigation for the treatment of COVID-19 as a daily 2-minute IV injection when added to the current standard of care.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see full prescribing information at <font style="text-decoration:underline;color:#000000;">www.CINVANTI.com</font>. </p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">IMPORTANT SAFETY INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Contraindications</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI is contraindicated in patients with hypersensitivity to any of the components of CINVANTI.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent use of pimozide with CINVANTI is contraindicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2odmt0mwibo000001.jpg" title="" alt="" style="width:181px;height:71px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Warnings and Precautions</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinically Significant CYP3A4 Drug Interactions</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Use of CINVANTI with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant drug.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-family:Courier New;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:Courier New;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:11pt;"><font style="font-family:Arial;">Use of pimozide with CINVANTI is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Use of CINVANTI with strong or moderate CYP3A4 inhibitors (</font><font style="font-style:italic;font-family:Arial;">e.g.</font><font style="font-family:Arial;">, ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to CINVANTI.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Use of CINVANTI with strong CYP3A4 inducers (</font><font style="font-style:italic;font-family:Arial;">e.g.</font><font style="font-family:Arial;">, rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of CINVANTI.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Hypersensitivity Reactions</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious hypersensitivity reactions, including anaphylaxis, during or soon after administration of CINVANTI have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. If hypersensitivity reactions occur, discontinue CINVANTI. Do not reinitiate CINVANTI in patients who experience these symptoms with previous use.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Decrease in INR with Concomitant Warfarin</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-administration of CINVANTI with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of CINVANTI with each chemotherapy cycle.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk of Reduced Efficacy of Hormonal Contraceptives</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of CINVANTI. Advise patients to use effective alternative or back-up methods of non-hormonal contraception during treatment with CINVANTI and for 1 month following administration of CINVANTI or oral aprepitant, whichever is administered last.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Use in&#160;Specific&#160;Populations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avoid use of CINVANTI in pregnant women as alcohol is an inactive ingredient for CINVANTI. There is no safe level of alcohol exposure in pregnancy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2odmt0mwibo000001.jpg" title="" alt="" style="width:181px;height:71px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;color:#1E1E1E;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Adverse Reactions</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most common adverse reactions are:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:11pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:11pt;color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:11pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Single-dose fosaprepitant with MEC (&#8805;2%): fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, pain in extremity.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">3-day oral aprepitant with MEC (&#8805;1% and greater than standard therapy): fatigue and eructation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Single-dose fosaprepitant with HEC: generally similar to 3-day oral aprepitant. In addition, infusion site reactions (3%) occurred.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Single-dose CINVANTI (&#8805;2%): headache and fatigue. The safety profile of CINVANTI in healthy subjects who received a single 2-minute injection was similar to that seen with a 30-minute infusion.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Heron Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, visit<font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">www.herontx.com</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking Statements</p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="_Hlk479741885"></a>&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: the timing and results of the studies for the HTX-019-202 development program; the potential market opportunity for HTX-019-202; and other risks and uncertainties identified in the Company's filings with the&#160;U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.</p>
<p style="text-align:justify;margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations and Media Contact:</p>
<p style="text-align:justify;margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Szekeres<br />Chief Legal, Business and Administrative Officer</p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc.<br />dszekeres@herontx.com</p>
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">858-251-4447</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g2odmt0mwibo000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2odmt0mwibo000001.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !A /<# 1$  A$! Q$!_\0
M'P !  (" P$! 0$           @)!PH$!08#"P(!_\0 5Q   00" @$ ! 8)
M#P<*!P  ! (#!08!!P ("1$2$Q05%ADA6-87(B,Q-W:6E]4*)#8X5E=9=WB4
ME;.TM=AA<71U@;:W&#(T.3I!0E&QPC6(D=37\/'_Q  = 0$  @(# 0$
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M.ID*H$NWCR8:ES<KTG/&5P]$:%;QM;@Q>1C$X3J18WKL?)LC,[7LV<TO<@I
M(*8Q]IMMENW0R6-A\UW@)UF.KLAAJ VV*J:N>F%8[%=:;O=(86PVZCURR@Q;
M[\Q2+V9$LES0#DEF']LF!E@C7DNQZ)[V3I(V%L*;0T\EGV[/M-@/=C>Z Z1]
M7^FNT=Q]+=[Y$-W;<W$Y+\(_&Y["90<'F:*XR</<=5>.>5'(U,)X?@7[*^VS
M9\%A3W]\+7N3-^^]>N.3RN"O0E8/]Z,E=QR;1/"\^DP2IO5+#)6-R,'S)0CP
M @Y5-E '6=V+CS ]T[.4<\46<;?;5(DGG/.DG'.24R9(9--*(4M\LHS!*27R
MGG%ND.NK>6I2G,YS])>B>7C<G0[H]G>_TBUD.G6T9O6(+O-N0KX&C6R1-/F9
M-GIZ;$&1S+(."@O/G5@; S5HW9JOD\C8L#6><B=VRQ[2)CVEXDL>9L(V1!&9
M24R9%)%,SQ.K)_&E%[)T@FR;SJ5@E:):+7 ETR%F8]D8>8;J9!8,C-/QQI0K
MQ,:F5/C8\=$A&N!'98CBV,$>Y&K0]\Z?^D ]T%9H9S!=(ME9B!=AA+-;WLT&
M*9*\O9&4XG DP>XDV<;2E]Z\H9Y\3)4@*0?5:L?';WKN LQ=O;?R]C"5$+=C
ME6J?A!9L([Q)[AM&LVUQ-B1@#K$D_#'B3F#+G8/Z?6G65#M$%VJ[;;LL%VO;
MYQT1HS6RY^P;2V.=(2#3L69<I*O!E3,O&,&-F/P]/9F\1H<B^01)L>T<S NN
MZ=[!LUZL5MV[RS5JY?<QB,+CB=8R-^6D,K98:@"<U4E!2NJ#_"@NXF<3/@3.
M?Z;9+:>W\U4ZE=3=X7LSF8<ZMLK;_I][<^XK+[ '5=F;%%+KEJLIT.93Q W?
M1TV6-.RN2+T$BV3X>07+1,7*.1TC$+DH\(]<3,-,,2T8HP9LA4?*,#$%CLR
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M /VOI;^+]M_-M4[>6W8?CMV!5=+5OHJC4]G[B2NX:>/KXOJM%1 <FV"XHUG
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MTKZ^#Y>MMNG_ *_+&[DUK#UJH>E=5N@5CB9]#W)</F!YB.<EMLO.?L?6:O\
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M.B;WM0-MQF,TEK&0C[7L(V6RC/NH,V. 0['4<9U?JJ>/N!D5GW;UUQHDJ9[
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M,Y]@A]3]0L)]>(+PX/C#>&3'@%$LHSCUVVW$H7G*L9SS([<SRMQXXLBFNRL
MWLA1\-IB926/N.IFSD(B.UA)DQCXX&8B?.-9';6?3N7&EDDUV5@&_D:'A-,3
M*3QUQU,V=P1$=K"3)C'QB)1$^<:Y&Z-G@Z8U=<MH2<67- TV+3*$Q0+S(Y9J
M%%C"8:8?(PIEM?K$I7ZSF,X]5.<>CTYQSGN3-JVY@\CG'(995CD>.:%$(,;$
ML!?:)'$B,\G$\S'Q1KGN;.JVS@<EG7H9:5C40\ZZB$&-B6K5VB9Q(C/+(GF8
M^*)UC^^;ZEZUL6EZPJ6LY.^V:YT>5O@[8]G@:V*#$Q!H );;Y,WE#+I&'9$?
M*$MKQE2<J]"<^KGT8G*[JL4LQC<'C\*[*W<CC'Y0(&]5I JO7:I3(([/JD?<
MX)B(GSCGR\M8C+;LLTLSC,%CL&[+7LGB[&6&!O5*2TUZ[4J9!'9X$C[G!Q S
MYQSY>4\<C[)F]OHSR/YVM>?_ ''.7OUNKV*;_.#$?^^N?OWNOV(;_.'$?^^N
M)=M\62K7776MHG4TG:+S?:5+W-Z%8M];B1Z^W +B69B-)EI%6(^0?$*E4,(?
M#<]B3[%;K'K(4G/.O)[JNT<GA\+7P#[V4RN-L9(JPY"G7"H-24#82=AOU)IK
M-\!!+GM/MDAYB==64W9>H93#82OM]U[*Y;%V,D58<C2KA3BI-<;*#L.^I.);
M+$!!JGM/MDAYB8U]GMJ;P$9<)(ZPV(AAA"G768G:&M#I)QM&,J6D(,J5C62B
M,IQGV3"S1\NK]#:5^LK&,\BSNYUB1GLBV8A$D0U\YA6NF(\YA:V/0)GQ\0RT
M.Z?*)YF-<RS^Z5B3#V-<, B2(:V=PC7R,1S,*4QZ!8?'UH2T)*>(B>9UD?4^
MT:KN:A0>Q::X?F#G4FH0-+!YCY>-/C#R8J5BI4'+CN!9"-D@R@R4-O/CK6U[
M84@D5QE]S,X#.4-R8JKF,;+?1;4,B L+\&PEJ&FAZ+"NXO#<ERS6<01A,CW+
M,UD)EFMOYZAN7$U<SC9=Z+;AL0%A4IL):AQU[%>PKDO#<ARF+.((PF1[EF:R
M$RPW$]L*=*[B^Q@B G1Z\7:)S7<!M9Y0?Q(L&T*U& RTW0@7L.>\MR0HY108
MICZ4!RDS%2,3&Y*)85G$<K[]QS]Q>\D5;05&7K.'J9XI7[V6\Y22I]K%*+GO
MARQ8:P8<0M]E#JZ9,QU&Z_4#&V-Q^\45+0TV7K6&J9\I7[UW,[20JQ:Q*BY\
M2'+!C%K:<0NQ9KNKHEAASK)N]=M!:-U;9-H2$(;8A:Z_7!E0T>4.&6:[9;5"
M545+11>,CLX9*G&275.X]&667$X]"E)SS-[ISZ]KX*[G&UF7 IE3":R3!;&E
M<O5J(0)LY >T[(F4E_HC,?',:S>Z]PKVM@;N==59="F5()K)8"F-*[?JT%P+
M&<@/:RT)E)?Z(S$><QKRGV3-[?1GDL_Y,;:UWZ?]GI(QC_ZYQC_+SP>_6Z?8
MIO\ .#$?_P!:\'OWNOV(;_)N'#_\RB/_ #C7EB>V->CJ-NRP3=(M==N>@0 #
MM@ZTF7H7$RPQ,A^_P1D3-Q$A+U^6B)P-#[T?)"F*S^MW4%"BKRUASPGOVHG%
M[FMV<9?J9+::E,RV%LE6BP(V5^+597LUVV*CZ]I<$27 R9]0H-83V]W@9U!I
MIQ6Y[EK%WZ>3VBI+<OA+)5O21"ROQ:C:]JNZQ3L5[2X(DN6R9]0H8M<]O=WP
M&V=W20(4B)UIDEBGB#FC+5MC7J%*'*90^RI2%/X4A2FW$YRE6,*3G/HSCTXY
MZE9_<[E*<O9;I!JP:$SG\3$R#!@QF8F>8GB8\I^+7K5N#=+E*<O9+I!JP:$S
MN'$1,@P8,9F)GF)XF/*?BU]+/O&VZ^U=LC9^Q]0R=4"H,2)+C1+-SK%A+LC3
MK[C!C0K\0MUB-6"K(F<Y.QZ",%?<?3[!WT?M[<^0Q&#S.;S.WG4%XFNNP%<<
ME2MG=$CD&"!U^13*I\/GQ8X/Q/5^M+7[>W3D,/@LUG<UMUU!6(KKL!7#)T;C
M+HD<@P0.OR*)5/A\RV.#AGJ\]I:D& 6D\$(Y"%-H-$&+2VK.,J0DEE#R4*SC
MYLJ3A>$YSCYLYQ\W)<ED-4IL1Q#5@R(GSF(,8*(G_5SQJ8*9#5*;$3$-6#(B
M?CB#&"B)_ACGC6([GM]-6V74]6 U<ZP6.YTF_6^$RQ) QPKK]'9C5)@WGC<8
M0P_-D2@XPYSJTB!YPMXK[GCF R6X?0<U0P2J+;=S)8S+9"M(N4E<EBQ1,5B)
MGD)63>  TIA:_,C\M1W)[CBAF\?@54&W+N3Q>7R-7L<I*R/%@F8JD3?("M$\
M0!I3"U3R3/5UB7879+9NKX(6QV_KE,A11D_7ZRPZ-LZB'.*E[/*C0T0SED5Q
M;B6WCRF6W'\XPTPA6775)0G.>1_+[SS>#JA<R&SK"T,MU*0D&<Q;2FQ=>%>N
M/:$S,"33&)*?5&)[BF(C4?S&]<Y@:@7<CLRPNNRW3H@2\[BVE-B\\*U<>T.9
M@2:P8(I]4(GN*8B-9+B]E;5R2Z[:M$GU2 #C9>1D9U6Q:7-X$1&1)L@RUB,B
MW5G$*/)&9CT*93E(ZRDDO?<&7.9I&:SW>17]K-H5%IL.=:]^,=:\.$5VN$?
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>hrtx-20200716.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-07-16T05:17:58.7578354+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : 6bb28e030a8f480c8f036c0d59d66bf2 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:hrtx="http://www.herontx.com/20200716" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.herontx.com/20200716" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.herontx.com/20200716/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20200716_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20200716_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>hrtx-20200716_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-07-16T05:17:58.7578354+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : 6bb28e030a8f480c8f036c0d59d66bf2 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>hrtx-20200716_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-07-16T05:17:58.7578354+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : 6bb28e030a8f480c8f036c0d59d66bf2 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.herontx.com/20200716/role/TemplateLink" xlink:href="hrtx-20200716.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="hrtx-20200716.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>hrtx-8k_20200716_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrtx-20200716.xsd" xlink:type="simple"/>
    <context id="C_0000818033_20200716_20200716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
        </entity>
        <period>
            <startDate>2020-07-16</startDate>
            <endDate>2020-07-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000818033_20200716_20200716" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000818033_20200716_20200716" id="F_000004">0000818033</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000818033_20200716_20200716" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000818033_20200716_20200716" id="F_000002">2020-07-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000818033_20200716_20200716" id="F_000003">Heron Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000818033_20200716_20200716" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000818033_20200716_20200716" id="F_000006">001-33221</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000818033_20200716_20200716" id="F_000008">94-2875566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000818033_20200716_20200716" id="F_000009">4242 Campus Point Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000818033_20200716_20200716" id="F_000010">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000818033_20200716_20200716" id="F_000011">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000818033_20200716_20200716" id="F_000012">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000818033_20200716_20200716" id="F_000013">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000818033_20200716_20200716" id="F_000014">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000818033_20200716_20200716" id="F_000015">251-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000818033_20200716_20200716" id="F_000016">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000818033_20200716_20200716" id="F_000017">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000818033_20200716_20200716" id="F_000018">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000818033_20200716_20200716" id="F_000019">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000818033_20200716_20200716" id="F_000020">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000818033_20200716_20200716" id="F_000021">HRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000818033_20200716_20200716" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000818033_20200716_20200716" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140078814229320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 16,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Heron Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-2875566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4242 Campus Point Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ'7N0;#W\!J-'<V/'[?\ 5!+ P04    "  &1?!0)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ !D7P4&60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M"  &1?!0!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    (  9%\%"E=U"K[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  9%\%"97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ !D7P4#??NB=9!   ]1   !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  9%\%"#J:4#
MU $  #(&   -              "  9P,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ !D7P4)>*NQS     $P(   L              ( !FPX  %]R96QS
M+RYR96QS4$L! A0#%     @ !D7P4!PX9>H_ 0  / (   \
M ( !A \  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  9%\% D'INBK0
M /@!   :              "  ? 0  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    (  9%\%!ED'F2&0$  ,\#   3              "
M =41  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  !\3
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hrtx-8k_20200716.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="hrtx-8k_20200716.htm">hrtx-8k_20200716.htm</File>
    <File>hrtx-20200716.xsd</File>
    <File>hrtx-20200716_lab.xml</File>
    <File>hrtx-20200716_pre.xml</File>
    <File>hrtx-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "hrtx-8k_20200716.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "hrtx-8k_20200716.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrtx-20200716_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrtx-20200716_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "hrtx-20200716.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hrtx",
   "nsuri": "http://www.herontx.com/20200716",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hrtx-8k_20200716.htm",
      "contextRef": "C_0000818033_20200716_20200716",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hrtx-8k_20200716.htm",
      "contextRef": "C_0000818033_20200716_20200716",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "verboseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20200716/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001564590-20-032445-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-032445-xbrl.zip
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M0!&"=A@-O3#R.I%EO\#&OGZ5#WI;E%()%',C82E!$;*J%2$S[D:E*1K6X$"
MRU-F2I++#D$GS!#D8%]RN=X[_1+SE,FU24S-'O:CGF76^F*YKU[C45S=H"!6
MT#MQ.R HIRT@S)S>U 2'"(,$"?<Q#4F[L[\OHIF(.\X*?B=012E5SF++C]*<
M2;YQ&]D2'<@H8=_/6-'D.12EE?41_TO'<$?#X3 PU!)0SKGJ2:<0;:D.2'B-
MEFXA3=D3@%)R,L\EOD_Y:HP3F%,5QIS]FT-*$H)CU18IUCUMCZ%"EI OL'R
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MU&>YA"P&A3I0T5>O8AO77?-2;UZQU\%AI]WN5#MRL57<%[?_ 5!+ P04
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MG",[:=V*FR^WVK\<A:T[Y^?G=OC?=5..5 T%;,?^]N5VZ#W!F6N)5 D7>)*
MHQX/;]Y2+\Q1B;A ;@OYEY4TL^0MJ].UCCKM)?=;0@T (CT8Q? 13H#\_?5Q
MD,MY;LL6-H%381S_UAU#+&(.(9X8G*C[8<8RW60<YS*.SHF,XXT*+5C-13UP
M-)MCH8J]=ZAW,- ;[2:@[H ?($/4OR::15;#-A/\,'"99M7S@'4/8"3F-Z@W
M]&U([4'3P,6:@]Z"U!AT#6\$VW'N:X2)R\<AC5B2IZX[CZBP!+7=)>)7<.(N
M<* ,,PQQ"T"N4C;$ 9=W)!JWHK6U$\^\;Q2X^8&'H<C5/FXI$0L6A2C\: E*
M(<-E (D/XUE_C4V]K7'Q9& <>NTI?;9]B 1TYUQ>6/(B-1)QZ_LU"5"PZHLM
M"'/Q0) L_X"K+#N6BQEER<UP2!>M@LYV-DS97JZHXDKNGB"QO@[+@GW'XPU[
M,,CI@H7+;6E%@]?R_131@)@'A$1 ,'VT7P/:CO^2>9DH7.8E 8C+'3'$+6R/
MBFW"/+!PVO031F>%:L:T=*=*MGYW]*G8 U^.N2#S@K*NV.A4SPT9$#TNB&3_
M%"*#?Q+L?P^?>+7*-%>(!A*=G$-&8I!E\YSM4R_-:0S]M;X^74GXP^=9*3+-
M$\(407$E+768\5+P^)+K!KO3LF[<Z%1/O0R(?C^NX8'$/[PAU4+37"V,$157
MTU/G#+D^A,G'+U6GRHW.^Y5X!JS!R3/B 8(H?.1T>-L6IX+N5,DXV3>GV-**
MZSL!/,(IDGL,$MRYL]*^5O?=9_^?Q6IL^_]* R3/X3U=F 6Z2R'3%,?UQ3[L
M23$;>(5#HKY*O)Y!-D5D^CNC+\%3G\[F+JEX(L^!V,<E2LC&RC-A Q$=B/E,
M*=/B%-&2NAF:#KQ?)O05P@W"\&XQ&T-6S?WI?OMH_(K3F,\E!8@X3/&V0G5:
MI(I)"N/JXNJSZX!XE,TI"U_X&P9BW]:G"[%^K/K4K[BAV@&UC^2%T(WY/,/Z
M'H2\@#(0<P-);DH!E,LCK2BJX3G#^>F*LU4N5?K*:>0N![[8?Z$)BEY+K[,4
MY(+LDXX<T,:*1_"!+*%A2\:N5-'2ZAF;%KQO1O05QJ7OBQ'P^-<M(K!3K2B4
M /LHKP!LK!ABDO?)A7PK%03WQ)CEHR@]M)1J1J8"J[*024+G,.;O[FO^KF[%
MNS_8_*,7:J[YNV7-WVW"_)I2L=O\W1]H_KZXO&<C^D)J63_=78/:KW#-VUYR
MR6.#9#/,\HJDJ R_J9:!"5";/93^?I?TVKT>GCWNV0.CSXAX%8_1>1@:1-_
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M<')E+GAM;.5:6X_B-A1^K]3_X&9?=M4F<6"X#!IV19F9%2HS@X"VJ[ZL@F/
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M!*-80$ZH8D3_-8EMVF;1W"]:M2NSVK3VF]6ZL5_=KY>KE;^99M,T,QW\&B^
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M6(_MPWQDP&-VEA?A%"C#]H^.?^L?GQ_MF:(D3#7$K9??SY*@!Y-$T,=&'.V
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M&"Q6 &P.\"W1UEYW$>T'KQWS;3 M I'EL- P%#Y2R$9L_13X![@"X )8&[D
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MS.!!%%T%70>:M*T%*@5P1$VCD&H1TU?032D,R.%^M@8(%%H^!L$DX0<>09K
M&S6$QGX>&)5*^#,>-.P:U,GM!==1#L$&:5:@Q"L23B PBW@< _=?S/,)>'(J
M;7H*C04CM3,2L(+8URAJ@(5X(<#,"0OAZ([P1M0-@1P&!R@'$F6\[-]B(CY>
M:VX&>2KDPP9#:QNU ''0F2,[2,)"1* U82T3E1)S$"P#8O$K_ ),%M>9!@@"
M? _/ V0;H*\< JW3'*<ARK$CY+I1TU2OJJ9Y8ES!.!Z..5FI-&VOR?IAZ$)[
M,9J=U; 2L&SMG,#2!S"&ST#T:.RE$'XD\2/#/BMR;Z09&#6,(QU9?<R#:*;A
M"4=9!N\1:4X](%FY6Q;X#+&(1=.0I@/:+ T)YR_$%&DE0]1@.".GXCS'9RJX
M$'EIVW-)BB+W\E,IH9I2X]2J2#]-$U1E?Q4P5VL]P'"]@=EB,S92W<:86UV.
M+?::\!FJI+HI99&!&GMK\=#486X@4C$$&Z)AQ03\EP2IFB*'V;;-'-18,?!K
MBV_=W.\,)'O)!-<J1(@L4OD7R !Q"#EF,$'-R$0"@,DC%=KN9V:+WL!*3<ZI
M2>_D <?'1@$7#876%N>!.6PPY-WY?YK@6#7!G;;F$*C3- 2;$YRR!BY^( :J
M":N?:W"I\+-0%:!3FH,89P9_>]_0^F"A0-BPG51JV(J5&"*:!%/2)H8/A<40
M\(919$(N$6:4<1IC1F=W-^'[J;%,?:/RN)GSO'Z T:$Z"KD."<:X)M0%Z@ ?
M5\87C12'C@ZX%3)0& 9AC$QXYX\L=FEY"% Z!XPD2$.I05,2"* 1T]G>)2A
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MCD2I,_AP:%U1\&]J<=*[Y4X>P<#[.XFQQR0WFA.]SBXJ[M)9S8#B(@%R@RF
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M:+3/T5\N7PG.X%D5_6#[?YR\Z&_:$Q1'J"AXL++)[A34K^WQ-3XFB+%.S-N
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M-U%@ 2R[/<B57@W+NH/U2S/*.EE8N+^"1#IQ9W SDRND7Y5*\TCXQ;OYEJ,
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M_P-02P$"% ,4    "  '1?!0EE.%RK4$  "Y%@  $0              @ $
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B+65X.3DQ7S8N:'1M4$L%!@     %  4 10$  ,DX      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
